Search Results
Aug 28, 2026, 12:23 ET LifeTech Scientific Corporation Announces 2026 Interim Results
Cera™ PFO Occluder, CeraFlex™ PFO Occluder, FuStar™ Steerable Introducer, SeQure™ Snare System and SteerEase™ Introducer have obtained the CE MDR certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;Cera™ PFO Occluder,
More news about: LifeTech Scientific Corporation
Aug 26, 2026, 10:01 ET Tractor Front Tires Market to Reach USD 3.23 Billion by 2035, Reports Radial Insights
tire distribution channels.In July 2025, Trelleborg Tires launched the TM800 PowerFlex for medium- and high-powered tractors, combining VF-PFO construction, ProgressiveTraction lugs and a central rib designed to improve field traction and road stability.Executive Q&A SummaryQ:
More news about: Radial Insights
Aug 07, 2026, 05:01 ET Agricultural Tires Market to Reach USD 15.84 Billion by 2035 Says Radial Insights
replacement market share.In July 2025, Trelleborg Tires introduced the TM800 PowerFlex for medium- and high-powered tractors. The product combines VF-PFO construction, ProgressiveTraction lugs and a road-focused central rib to support field-to-road performance, lower soil compaction and longer service
More news about: Radial Insights
Jun 18, 2026, 01:46 ET MediSun Energy and Yanrun Announce Strategic Joint Venture at SIWW 2026 to Drive Global Advanced Water Treatment and Zero Liquid Discharge Solutions
including Electrodialysis Bipolar Membrane (EDBM), Electrodialysis Metathesis (EDM), Electrodialysis (ED) stack systems, and Pressurised Forward Osmosis (PFO) systems, alongside integrated Zero Liquid Discharge (ZLD) solutions.By combining MediSun Energy's extensive international network and proprietary
More news about: MediSun Energy
Mar 31, 2026, 12:40 ET LifeTech Scientific Corporation Announces 2025 Annual Results: Steady Revenue Growth with Adjusted Net Profit Increasing 24.9%
and Congenital Heart Defect Occluder are currently at the stage of pre-registration clinical enrollment in China;Cera™ PFO Occluder has completed pre-marketing clinical enrollment and is currently under clinical follow-up in China;IBS Titan™
More news about: LifeTech Scientific Corporation
Jan 27, 2026, 09:07 ET BURL CONCEPTS ANNOUNCES FIRST HUMAN USES OF FOQUS™ ULTRASOUND SYSTEM FOR PATENT FORAMEN OVALE (PFO) DETECTION
cryptogenic stroke have a PFO. The FOQUS test is fully automated and can be completed in 40 seconds without sedation. As a result, the test can be performed by a single nurse and does not require the presence of a cardiologist or anesthesiologist, allowing rapid PFO testing to be performed anywhere,
More news about: BURL Concepts
Dec 03, 2025, 09:32 ET Recross Cardio Announces First Patient Enrolled in PROTEA-PFO US-Early Feasibility Study
clinical implantation with its novel PFO Sealing system in the PROTEA-PFO Early Feasibility Study (EFS). The procedure was successfully performed by Dr. Carey Kimmelstiel and his interventional team at Tufts Medical Center in Boston, Massachusetts. The PROTEA-PFO EFS (NCT07172464) is a prospective,
More news about: Recross Cardio Inc
Oct 21, 2025, 11:03 ET BURL CONCEPTS CLOSES CURRENT OVERSUBSCRIBED $4.5 MILLION INVESTMENT
reflects the market's recognition that a new way to assist physicians in PFO diagnosis in cryptogenic stroke patients is ripe for innovation," said Peter van der Sluis, CEO of BURL Concepts. "Similar to ECG testing for arrhythmias, PFO testing should be performed at a cardiologist's office instead of a lab
More news about: BURL Concepts
Oct 07, 2025, 06:00 ET NOBLES MEDICAL TECHNOLOGY II ANNOUNCES FDA APPROVAL TO RESTART NOBLESTITCH™ CLINICAL TRIAL
from cryptogenic stroke and other PFO-related conditions. We paused the trial to make a more robust protocol and data collection. The recently published data validates what we have long believed—that a suture-mediated, non-implant approach represents the future of PFO closure. The completion of the trial
More news about: Nobles Medical Technology II, Inc.
Sep 16, 2025, 19:50 ET NobleStitch™ Suture-Mediated PFO Closure Demonstrates Superior Long-Term Safety and Outcomes in Largest Cohort to Date
/PRNewswire/ -- NobleStitch™, the deviceless suture-mediated patent foramen ovale (PFO) closure system distributed worldwide by HeartStitch, Inc., today announces robust long-term clinical results from the largest cohort ever reported for PFO closure, underscoring its unparalleled safety and efficacy. Published
More news about: HeartStitch® Inc.